Summit Therapeutics Inc.
SMMT
Rank in Stocks
#1666
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Share Price
$16.08
Market Cap
$12.83B
Change (1 day)
3.29%
Change (1 year)
-19.75%
Country
US
Trade Summit Therapeutics Inc. (SMMT)
Category
Healthcare
Number of shares outstanding for Summit Therapeutics Inc. (SMMT)
Number of shares outstanding as of June 2026: 778.18M
According to Summit Therapeutics Inc. latest financial reports and stock price the company's current number of shares outstanding is 778.18M. At the end of December 2023 the company had 619.65M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Summit Therapeutics Inc. (SMMT) from 2004 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 778.18M | 8.30% |
| 2024 | 718.54M | 15.96% |
| 2023 | 619.65M | 220.50% |
| 2022 | 193.34M | 109.60% |
| 2021 | 92.24M | 32.67% |
| 2020 | 69.52M | 112.44% |
| 2019 | 32.73M | -49.67% |
| 2018 | 65.03M | 5.65% |
| 2017 | 61.55M | 4.14% |
| 2016 | 59.10M | 49.25% |
| 2015 | 39.60M | 34.68% |
| 2014 | 29.40M | 85.99% |
| 2013 | 15.81M | 35.99% |
| 2012 | 11.63M | -69.55% |
| 2011 | 38.18M | -43.03% |
| 2010 | 67.01M | 25.51% |
| 2009 | 53.39M | 11.45% |
| 2008 | 47.90M | 31.53% |
| 2007 | 36.42M | 16.31% |
| 2006 | 31.31M | 33.45% |
| 2005 | 23.47M | 23.35% |
| 2004 | 19.02M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | -67.37% |
US
|
|
| 396.00M | -49.11% |
US
|
|
| 478.91M | -38.46% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -92.01% |
NL
|
